A novel anti-metastatic treatment against triple negative breast cancer
Triple negative breast cancer (TNBC) is an aggressive type of breast cancer with great metastatic propensity. TNBC lacks expression of oestrogen receptors, and as such, there are fewer targeted and efficient treatment options. The EU-funded CanceRusolution project has developed a cytostatic drug that targets the cytoskeleton of TNBC cells, halting their metastatic potential and hence their aggressiveness. Researchers plan to test the treatment in an animal model of TNBC and perform pharmacokinetics analysis. Upscaling treatment production to clinical grade will pave the way towards clinical testing of the treatment, with significant ramifications for the future management of TNBC.
Fields of science
- HORIZON.3.2 - European innovation ecosystems Main Programme
Call for proposalSee other projects for this call
Funding SchemeHORIZON-AG-LS - HORIZON Lump Sum Grant
See on map